Skip to content
The Policy VaultThe Policy Vault

methylphenidate — CareFirst (Caremark)

Narcolepsy

Initial criteria

  • Authorization may be granted when the patient has a diagnosis of narcolepsy when ALL of the following criteria are met:
  • This request is NOT for amphetamine extended-release (Adzenys ER, Adzenys XR-ODT), amphetamine-dextroamphetamine extended-release (Adderall XR), amphetamine sulfate orally disintegrating tablet (Evekeo ODT), methylphenidate chewable tablet, methylphenidate immediate release, methylphenidate extended-release (Aptensio XR, Concerta, Cotempla XR-ODT, methylphenidate CD, Methylphenidate Osmotic Extended-Release, Relexxii, Ritalin LA), dexmethylphenidate (Focalin), or dexmethylphenidate extended-release (Focalin XR).
  • The requested drug is being prescribed by, or in consultation with, a sleep specialist.
  • The diagnosis has been confirmed by a sleep study.

Reauthorization criteria

  • Authorization may be granted when the patient has a diagnosis of narcolepsy when ALL of the following criteria are met:
  • This request is NOT for amphetamine extended-release (Adzenys ER, Adzenys XR-ODT), amphetamine-dextroamphetamine extended-release (Adderall XR), amphetamine sulfate orally disintegrating tablet (Evekeo ODT), methylphenidate chewable tablet, methylphenidate immediate release, methylphenidate extended-release (Aptensio XR, Concerta, Cotempla XR-ODT, methylphenidate CD, Methylphenidate Osmotic Extended-Release, Relexxii, Ritalin LA), dexmethylphenidate (Focalin), or dexmethylphenidate extended-release (Focalin XR).
  • The patient has achieved or maintained improvement in daytime sleepiness with narcolepsy from baseline.